CYTKCYTOKINETICS INC
Pharmaceutical Preparations
- Revenue
- $88M
- 377% YoY
- Operating margin
- -695.4%
- 76% YoY
- EBITDA
- −$602M
- 14% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $747M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired128% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $70M | $95M | $8M | $18M | $88M | 377% |
| Operating income | −$186M | −$324M | −$496M | −$536M | −$612M | 14% |
| Net income | −$215M | −$389M | −$526M | −$590M | −$785M | 33% |
| Operating cash flow | −$143M | −$300M | −$414M | −$396M | −$510M | 29% |
| Capex | $49M | $11M | $1M | $4M | $25M | 535% |
| Stock-based comp | $27M | $48M | $72M | $98M | $112M | 15% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $9M · 10
- Net
- −$9M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $12M | $16M | 306 | 120 |
| FY2024 | $14M | −$2M | 443 | 114 |
| FY2023 | $9M | $21M | 787 | 115 |
| FY2022 | $9M | $9M | 432 | 111 |
| FY2021 | $6M | $20M | 430 | 125 |